Tower Research Capital (TRC)’s PDS Biotechnology PDSB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-2,220
| Closed | -$1.71K | – | 5446 |
|
|
2025
Q4 | $1.71K | Buy |
+2,220
| New | +$2K | ﹤0.01% | 4650 |
|
|
2025
Q3 | – | Sell |
-2,002
| Closed | -$2.66K | – | 5520 |
|
|
2025
Q2 | $2.66K | Sell |
2,002
-7,359
| -79% | -$9.99K | ﹤0.01% | 4611 |
|
|
2025
Q1 | $11.1K | Buy |
9,361
+4,306
| +85% | +$6.12K | ﹤0.01% | 3568 |
|
|
2024
Q4 | $8.24K | Buy |
5,055
+2,284
| +82% | +$6.04K | ﹤0.01% | 4005 |
|
|
2024
Q3 | $10.6K | Sell |
2,771
-12,174
| -81% | -$40.6K | ﹤0.01% | 3739 |
|
|
2024
Q2 | $43.8K | Buy |
14,945
+10,792
| +260% | +$34.5K | ﹤0.01% | 3200 |
|
|
2024
Q1 | $16.4K | Sell |
4,153
-4,893
| -54% | -$25.2K | ﹤0.01% | 3181 |
|
|
2023
Q4 | $45K | Buy |
9,046
+7,612
| +531% | +$37.8K | ﹤0.01% | 3203 |
|
|
2023
Q3 | $7.24K | Sell |
1,434
-1,168
| -45% | -$6.4K | ﹤0.01% | 4490 |
|
|
2023
Q2 | $13.1K | Buy |
2,602
+834
| +47% | +$5.46K | ﹤0.01% | 3805 |
|
|
2023
Q1 | $11K | Sell |
1,768
-506
| -22% | -$4.14K | ﹤0.01% | 4248 |
|
|
2022
Q4 | $30K | Sell |
2,274
-11,717
| -84% | -$82.7K | ﹤0.01% | 2749 |
|
|
2022
Q3 | $42K | Buy |
+13,991
| New | +$59.4K | ﹤0.01% | 3320 |
|
|
2022
Q2 | – | Sell |
-124
| Closed | -$1K | – | 6414 |
|
|
2022
Q1 | $1K | Sell |
124
-9,797
| -99% | -$60.9K | ﹤0.01% | 5833 |
|
|
2021
Q4 | $80K | Sell |
9,921
-8,076
| -45% | -$86.9K | ﹤0.01% | 2384 |
|
|
2021
Q3 | $269K | Buy |
17,997
+14,806
| +464% | +$185K | 0.01% | 1520 |
|
|
2021
Q2 | $40K | Sell |
3,191
-20,256
| -86% | -$158K | ﹤0.01% | 3213 |
|
|
2021
Q1 | $107K | Buy |
+23,447
| New | +$94.4K | ﹤0.01% | 2540 |
|
|
2020
Q4 | – | Sell |
-2,717
| Closed | -$6K | – | 5343 |
|
|
2020
Q3 | $6K | Buy |
+2,717
| New | +$7.62K | ﹤0.01% | 4301 |
|
|
2019
Q2 | – | Sell |
-370
| Closed | -$3K | – | 4128 |
|
|
2019
Q1 | $3K | Buy |
+370
| New | +$3.09K | ﹤0.01% | 3309 |
|
|
2018
Q3 | – | Sell |
-128
| Closed | -$3K | – | 4133 |
|
|
2018
Q2 | $3K | Buy |
+128
| New | +$2.67K | ﹤0.01% | 3245 |
|
|
2018
Q1 | – | Sell |
-169
| Closed | -$31K | – | 3690 |
|
|
2017
Q4 | $31K | Buy |
169
+23
| +16% | +$4.63K | ﹤0.01% | 1715 |
|
|
2017
Q3 | $32K | Buy |
146
+86
| +143% | +$17.8K | ﹤0.01% | 2385 |
|
|
2017
Q2 | $12K | Buy |
+60
| New | +$11.8K | ﹤0.01% | 1516 |
|
|
2017
Q1 | – | Sell |
-3
| Closed | -$1K | – | 3693 |
|
|
2016
Q4 | $1K | Sell |
3
-96
| -97% | -$21.8K | ﹤0.01% | 3640 |
|
|
2016
Q3 | $21K | Buy |
+99
| New | +$19.6K | ﹤0.01% | 1585 |
|
|
2016
Q1 | – | Sell |
-26
| Closed | -$6K | – | 4713 |
|
|
2015
Q4 | $6K | Buy |
+26
| New | +$8.38K | ﹤0.01% | 2800 |
|
Other funds holding PDSB
VCM
VFT
IWA
AC
Tower Research Capital (TRC)'s PDSB Position: Q1 2026 in Review
Tower Research Capital (TRC) sold out of PDS Biotechnology (PDSB) in Q1 2026, closing a stake of 2,220 shares — an estimated $1.71K sold.
Tower Research Capital (TRC) first reported a position in PDSB in Q4 2015 and held it in 27 quarters. The position peaked at $269K in Q3 2021. 41 funds tracked by Wall St. Rank hold PDSB as of Q1 2026.
- Tower Research Capital (TRC) reported no remaining PDS Biotechnology position as of Q1 2026 after selling out during the quarter.
- Tower Research Capital (TRC) sold 2,220 PDS Biotechnology shares in Q1 2026, an estimated $1.71K.
- Tower Research Capital (TRC) first reported a position in PDS Biotechnology in Q4 2015 and held it in 27 quarters.
- Tower Research Capital (TRC)'s PDS Biotechnology position peaked at $269K in Q3 2021.
- 41 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.